Related Experiment Video

Updated: Jul 12, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Cannabidiol arrests onset of autoimmune diabetes in NOD mice

Lola Weiss1, Michael Zeira, Shoshana Reich

  • 1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel. lolaw@hadassa.org.il

Neuropharmacology
|August 24, 2007
PubMed

Insights

Cannabidiol (CBD) treatment significantly reduces diabetes incidence in non-obese diabetes-prone mice. CBD also ameliorates disease symptoms and modulates key inflammatory cytokines, suggesting therapeutic potential for type 1 diabetes.

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease characterized by pancreatic islet destruction.
  • Previous research indicated that cannabidiol (CBD) may lower T1D incidence in young NOD mice.
  • NOD mice serve as a valuable model for human T1D research.

Purpose of the Study:

  • To investigate the therapeutic efficacy of cannabidiol (CBD) in established or pre-diabetic NOD mice.
  • To evaluate the impact of CBD on diabetes incidence, progression, and associated immune markers.
  • To assess the potential of CBD as a treatment for type 1 diabetes.

Main Methods:

  • Administration of CBD to 11-14 week old female NOD mice at latent or early symptomatic stages of diabetes.
  • Monitoring diabetes incidence and progression in CBD-treated, emulsifier-treated, and untreated control groups.
  • Quantification of pro-inflammatory (IL-12) and anti-inflammatory (IL-10) cytokines in splenocytes.
  • Histological examination of pancreatic islets to assess tissue integrity.

Main Results:

  • Diabetes incidence was significantly lower in the CBD-treated group (32%) compared to controls (86-100%).
  • CBD treatment led to a significant reduction in pro-inflammatory IL-12 and a significant increase in anti-inflammatory IL-10 levels.
  • Histological analysis revealed better preservation of pancreatic islets in CBD-treated mice.

Conclusions:

  • Cannabidiol (CBD) effectively ameliorates diabetes manifestations in established or pre-diabetic NOD mice.
  • CBD modulates key cytokine profiles, reducing inflammation and promoting an anti-inflammatory state.
  • These findings support the potential of CBD as a safe and effective therapeutic agent for type 1 diabetes treatment.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...